| Revenue growth | 15% YoY growth in Q1 FY27. |
|---|---|
| Margins | Gross margin improved to 33% from 30% YoY. |
| Demand visibility | Cyclical; H2 generally stronger for regulated markets due to winter season. |
| Management confidence | High on long-term value from new product platforms and integration. |
Growth
Revenue increased from INR 263Cr to INR 304Cr; EBITDA improved from INR 10Cr to INR 25Cr YoY.
Outlook
Commissioning 7-ACA project (INR 750Cr capex) and Cefiderocol by March 2027; targeting global Exblifep expansion.
Risks
Industry facing overcapacities and cutthroat pricing pressure; regional conflict in Middle East impacting commercial rollouts.
Last quarter's promises, checked
Delivered
- Guided 10-15% base growth → delivered 15% YoY (= BEAT)
- Guided Q4 gross margin recovery → delivered 33% vs 30% YoY (= BEAT)
- Guided 7-ACA commissioning Q1CY27 → delivered On Track (= BEAT)
Partly delivered
- Guided Exblifep US deal closure Q1/Q2 → delivered advanced stages (= PARTIAL)
Missed
- Guided licensing deal every quarter → delivered zero new deals (= MISS)
Investor Presentation filed with BSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹1,064.90
- Market cap
- ₹6,377 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 735.8×Sector 50.4×
- Promoter holding
- 69.84%+0.00% QoQ
- FII holding
- 0.80%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Capital Structure Change
Orchid Pharma Limited received trading approval for 4,45,86,052 equity shares issued under its NCLT-sanctioned scheme of amalgamation, effective September 23, 2026.
Orchid Pharma Acquisition
Orchid Pharma purchased land in Patibulum Village, Kancheepuram District. This transaction concludes the previous lease arrangement with DBS Bank regarding the property.
Orchid Pharma Annual Report
Orchid Pharma has filed its Annual Report for the financial year 2025-26, which includes the notice for the company's 33rd Annual General Meeting.
Orchid Pharma Annual General Meeting
Orchid Pharma Limited has issued the notice for its 33rd Annual General Meeting scheduled for September 29, 2026, to conduct ordinary and special business.
Orchid Pharma Management Change
Orchid Pharma Limited announced the redesignation of Mr. Arjun Dhanuka as Executive Director and the appointment of M/s. J Karthikeyan & Associates as Cost Auditors.
Orchid Pharma Board Meeting Outcome
Orchid Pharma appointed a cost auditor and designated Mr. Arjun Dhanuka as a Whole-Time Director. The board also set arrangements for the upcoming 33rd Annual General Meeting.